PeptiDatabase
English EN
Heart & blood vessels

Carperitide

Not FDA-approved

Last verified: October 30, 2026

At a glance

FDA approval Not FDA-approved No record in Drugs@FDA
Randomized controlled trials 16 of 145 publications on PubMed
Registered clinical trials 3 0 active
Adverse event reports 341 332 classified as serious
  • Carperitide is not an FDA-approved drug: Drugs@FDA has no record of it.
  • PubMed lists 145 publications mentioning it, including 16 randomized controlled trials and 14 animal-only studies.
  • ClinicalTrials.gov lists 3 registered studies testing it (0 active).
  • FDA's adverse event system (FAERS) holds 341 reports mentioning it; 332 classified as serious. Reports do not prove causation.

Research topics

  • Atrial Natriuretic Factor 88
  • Heart Failure 73
  • Acute Disease 24
  • Japan 20
  • Blood Pressure 19
  • Natriuretic Peptide, Brain 16
  • Prognosis 16
  • Diuretics 15
  • Hospital Mortality 12
  • Hemodynamics 11

Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).

Regulatory status

Drugs@FDA applications

No application found in Drugs@FDA, FDA's database of approved drugs.

Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query

FDA compounding safety list

Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.

Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026

Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.

Scientific publications

  • All publications 145
  • Human (MeSH) 113
  • Animal only 14
  • Clinical trials 26
  • Randomized controlled trials 16
  • Systematic reviews & meta-analyses 5
  • Case reports 17
  • Retracted 0

Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.

Latest publications

Source: PubMed (NCBI) · verified October 30, 2026

Clinical trials

Registered
3
Active
0
With posted results
0

Conditions studied

  • Heart Failure 1
  • Renal Failure 1
  • Heart Failure, Congestive 1
  • Heart Decompensation 1
  • Left Ventricular Failure 1
  • Myocardiopathies 1
  • Systolic or Diastolic Left Ventricular Dysfunction 1
  • Respiratory Distress Syndrome 1
Study Status Phase Start
The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure
NCT00613964 Nara Medical University
Terminated Phase 4 May 2009
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
NCT00259038 Daiichi Sankyo
Completed Phase 2 Jan 2004
Carperitide in Acute Respiratory Distress Syndrome (ARDS)
NCT00030121 Suntory Pharmaceutical
Completed Phase 2 Dec 1999

All 3 studies on ClinicalTrials.gov ↗

Source: ClinicalTrials.gov · verified October 30, 2026

Adverse event reports

Reports
341
Serious
332
With death outcome
125

Most reported reactions

  • Cardiac failure 60
  • Renal impairment 34
  • Blood urea increased 22
  • Pneumonia 21
  • Hypotension 20
  • Blood pressure decreased 19
  • Dehydration 18
  • Platelet count decreased 18
  • Aspartate aminotransferase increased 17
  • Cardiac failure congestive 17
  • Cardiac failure chronic 16
  • Haemoglobin decreased 16

Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.

Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query

Change history

No changes since monitoring began on October 30, 2026.